A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradientYUEHUI YANG; YANLING MA; SHAONING WANG et al.European journal of pharmaceutics and biopharmaceutics. 2012, Vol 80, Num 2, pp 332-339, issn 0939-6411, 8 p.Article

Pharmacogenetic Pathway Analysis of IrinotecanROSNER, G. L; PANETTA, J. C; INNOCENTI, F et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 3, pp 393-402, issn 0009-9236, 10 p.Article

Targeting atypical trypanosomatid DNA topoisomerase IBALANA-FOUCE, Rafael; REDONDO, Carmen M; PEREZ-PERTEJO, Yolanda et al.Drug discovery today. 2006, Vol 11, Num 15, pp 733-740, issn 1359-6446, 8 p.Article

Validation study of assay method for DE-310, a novel polymer-bound camptothecin derivative, and the free drug in mouse plasma by liquid chromatography with fluorimetric detectionOGUMA, Toshihiro; KONNO, Tomomi; NAKAOKA, Minoru et al.Journal of chromatography. B. 2004, Vol 801, Num 2, pp 157-164, issn 1570-0232, 8 p.Article

Renal Function as a Predictor of Irinotecan-induced NeutropeniaDE JONG, F. A; VAN DER BOL, J. M; MATHIJSSEN, R. H. J et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 2, pp 254-262, issn 0009-9236, 9 p.Article

Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line ModelsALLEN, Wendy L; COYLE, Vicky M; JOHNSTON, Patrick G et al.Clinical cancer research (Print). 2008, Vol 14, Num 20, pp 6647-6655, issn 1078-0432, 9 p.Article

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effectsSAPRA, Puja; KRAFT, Patricia; PASTORINO, Fabio et al.Angiogenesis (London). 2011, Vol 14, Num 3, pp 245-253, issn 0969-6970, 9 p.Article

Enhancement of Radiation-induced DNA Damage and Inhibition of Its Repair by a Novel Camptothecin AnalogGE HUANG; HUIJUAN WANG; YANG, Li-Xi et al.Anticancer research. 2010, Vol 30, Num 3, pp 937-944, issn 0250-7005, 8 p.Article

Irinotecan Pharmacogenetics : Influence of Pharmacodynamic GenesHOSKINS, Janelle M; MARCUELLO, Eugenio; ALTES, Albert et al.Clinical cancer research. 2008, Vol 14, Num 6, pp 1788-1796, issn 1078-0432, 9 p.Article

Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacsXIANYI SHA; XIAOLING FANG.International journal of pharmaceutics. 2004, Vol 272, Num 1-2, pp 161-171, issn 0378-5173, 11 p.Article

Nigericin-mediated liposome loading of topotecan: Is nigericin a potential drug release regulator?JINGXIA CUI; CHUNLEI LI; CAIXIA WANG et al.International journal of pharmaceutics (Print). 2010, Vol 399, Num 1-2, pp 31-36, issn 0378-5173, 6 p.Article

Novel hexacyclic camptothecin derivatives. Part 1: Synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ringSHENG WANG; YUYAN LI; YONGHUI LIU et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 14, pp 4095-4097, issn 0960-894X, 3 p.Article

Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer PatientsSCHAIQUEVICH, Paula; PANETTA, John C; IACONO, Lisa C et al.Clinical cancer research. 2007, Vol 13, Num 22, pp 6703-6711, issn 1078-0432, 9 p., 1Article

Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicityCAO, Shousong; DURRANI, Farukh A; RUSTUM, Youcef M et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 1107-1111, issn 0344-5704, 5 p.Article

The Role of the Transition Metal Copper and the lonophore A23187 in the Development of Irinophore CT™PATANKAR, Nilesh; ANANTHA, Malathi; RAMSAY, Euan et al.Pharmaceutical research. 2011, Vol 28, Num 4, pp 848-857, issn 0724-8741, 10 p.Article

Formulation and Comparative Characterization of Chitosan, Gelatin, and Chitosan-Gelatin-Coated Liposomes of CPT-11-HCISHENDE, Pravin; GAUD, Ram.Drug development and industrial pharmacy. 2009, Vol 35, Num 5, pp 612-618, issn 0363-9045, 7 p.Article

Irinotecan plus carboplatin for patients with carcinoma of unknown primary siteYONEMORI, K; ADO, M; YAMANAKA, Y et al.British journal of cancer. 2009, Vol 100, Num 1, pp 50-55, issn 0007-0920, 6 p.Article

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid TumorsTSE, Archie N; KLIMSTRA, David S; KI CHUNG et al.Clinical cancer research (Print). 2008, Vol 14, Num 20, pp 6704-6711, issn 1078-0432, 8 p.Article

P-Glycoprotein and Breast Cancer Resistance Protein : Two Dominant Transporters Working Together in Limiting the Brain Penetration of TopotecanDEVRIES, Nienkea; JIN ZHAO; KROON, Emily et al.Clinical cancer research. 2007, Vol 13, Num 21, pp 6440-6449, issn 1078-0432, 10 p.Article

Smart Nanorods for Highly Effective Cancer Theranostic ApplicationsYINLONG YANG; XIUJUAN ZHANG; CAITONG YU et al.Advanced healthcare materials (Print). 2014, Vol 3, Num 6, pp 906-915, issn 2192-2640, 10 p.Article

Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft modelsMATSUZAKI, Takeshi; TAKAGI, Akimitsu; FURUTA, Tomio et al.Oncology reports. 2012, Vol 27, Num 1, pp 189-197, issn 1021-335X, 9 p.Article

Synergistic Effects of Irinotecan and Flavonoids on Ehrlich Ascites Tumour-Bearing MiceHORVAT KNEZEVIC, Anica; DIKIC, Domagoj; LISICIC, Duje et al.Basic & clinical pharmacology & toxicology (Print). 2011, Vol 109, Num 5, pp 343-349, issn 1742-7835, 7 p.Article

Association of carboxylesterose 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patientsSAI, Kimie; SAITO, Yoshiro; YAMAMOTO, Noboru et al.British journal of clinical pharmacology. 2010, Vol 70, Num 2, pp 222-233, issn 0306-5251, 12 p.Article

Optimization of irinotecan chronotherapy with P-glycoprotein inhibitionFILIPSKI, Elisabeth; BERLAND, Elodie; OZTURK, Narin et al.Toxicology and applied pharmacology. 2014, Vol 274, Num 3, pp 471-479, issn 0041-008X, 9 p.Article

Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluidKHATRI, Amit; GABER, M. Waleed; BRUNDAGE, Richard C et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 3, pp 721-731, issn 0344-5704, 11 p.Article